Ozari Health Reviews (2026): Is It Legit — and What Does It Really Cost?

Published by Weight Loss Provider Guide · Last verified: August 25, 2026

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

Disclosure: Ozari Health does not pay us. We are not an Ozari affiliate and we earn nothing whether you sign up with them or not. We do earn a commission if you enroll with some of the alternatives we mention later, at no extra cost to you. We list the downsides of those companies too. That's the deal.

The short answer

Ozari Health reviews are still thin — 15 public Trustpilot reviews when we checked — but nothing we found supports calling it a fake storefront. Ozari appears to be a real, operating, very new cash-pay telehealth platform. The catch is the price and the paperwork. That “$86 a month” is not a monthly bill. It is $257 charged up front for three months, and Ozari labels it for first-time GLP-1 users. After that, its live pages show $145 or $175 a month for semaglutide and $199 or $235 for tirzepatide. Ozari also publishes lower long-plan figures elsewhere, but its public pages do not clearly say which plan the starter renews into.

So here is our verdict in one line: Ozari is reasonable to consider if you are paying cash, you are new to GLP-1s, you can put $257 or $375 on a card today, you are comfortable with a compounded prescription, and you get the renewal price, dispensing pharmacy, and cancellation rule in writing before you pay.

Skip it if you need an FDA-approved brand, you want insurance help, you need to choose the pharmacy yourself, or you may need to stop quickly.

That last one changes our verdict. Ozari's homepage says “Cancel anytime.” Ozari's Terms of Service say something different. Its Refund Policy adds a third set of rules. Its own launch release adds a fourth.

We put those documents side by side. The money section is next, because the amount charged today is not the number most people see first.

Our verdict at a glance

What did we check — and what did we not test?

We think you deserve to know how much weight to put on this page.

We checked:

• Ozari's homepage, treatment pages, state pricing pages, pharmacy page, and GLP-1 FAQ
• Its Terms of Service, dated February 15, 2026
• Its Refund & Cancellation Policy, updated August 2026
• Its public Trustpilot profile and all 15 visible reviews, one by one
• Five Ozari press releases from May through August 2026
• Ozari's company-published pricing dataset and “true cost” pages
• FDA records for Pharmcore Inc. doing business as Hallandale Pharmacy
• Texas State Board of Pharmacy profiles for license 35264 and the separate license 34546
• The March 2026 Texas inspection documents tied to those licenses
• FDA rules and 2026 enforcement statements for compounded GLP-1 drugs
• Ozari's published prices against its press releases, legal pages, and other Ozari pages

We did not:

• Sign up as a patient
• Complete an intake
• Get a prescription
• Receive a shipment
• Test customer service
• Test cancellation
• Test the medicine
• Confirm the identity of every reviewer or testimonial author
• Confirm that every advertised plan appears at checkout in every state

Everything below comes from dated public documents you can open yourself. When two documents disagree, we show both. When a provider states something we could not confirm outside the provider's own material, we label it that way.

Is Ozari Health legit?

Ozari identifies the company operating its site as Ozari LLC. Its Terms use New York law, its releases call it New York-based, and its site names clinicians, pharmacy partners, prices, legal terms, and contact details. Nothing we found supports calling it a scam. But a May 19, 2026 nationwide launch announcement gives it a very short public track record, and several current Ozari documents do not agree with each other. The honest answer is: operating and probably legitimate, but not yet proven.

What Ozari actually is

Let's start with something a lot of these companies leave fuzzy on purpose.

Ozari is not your doctor. Ozari is not the dispensing pharmacy. Ozari is the platform connecting the pieces.

Its own Terms say Ozari LLC “does not engage in the practice of medicine and does not provide any healthcare services.” The setup has three parts:

1. The platform — Ozari. It runs the site, intake, account, and payment flow.
2. The clinician. An outside licensed provider reviews your information and decides whether to prescribe.
3. The pharmacy. A separate licensed pharmacy makes and mails the compounded prescription if one is prescribed.

That three-part setup is common in telehealth. It still matters. If the charge is wrong, the medicine arrives warm, or the label does not match what you were told, you need to know which part is responsible.

What checked out

Here is what we could confirm, and we want to give credit where it is earned.

The operating name is disclosed. Ozari LLC appears throughout the Terms. The Terms use New York law, and Ozari's releases describe the company as New York-based. We did not rely on that alone as proof of a state registration record.

They name clinicians. Ozari publishes Dr. Sean Arora, MD; Dr. Shannon Arora, MD; Dr. Michael Wasef, MD; Johanna Galyen, APRN; and Natalie Cabrera, PharmD. Named people give you something real to verify instead of a blank “medical team” page.

They name pharmacy partners. Ozari publishes Hallandale Pharmacy and VialsRx. That is better than making patients pay before naming any possible pharmacy. The exact legal-entity issue is still unresolved, and we cover it below.

Their basic FDA disclaimer is right. Ozari says compounded medications are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality. It also says they are not equivalent to approved brands.

No arbitration clause was present in the Terms we checked. We read the current Terms and found no forced-arbitration clause or class-action waiver. That can change, so the dated Terms control, not this sentence forever.

What did not line up

Now the other side.

Two phone numbers. Ozari's website footer lists (917) 267-8452. Its Trustpilot profile and press releases list (302) 316-5231. Two numbers can be legitimate, but the public pages do not explain which one handles patient care, billing, or cancellations.

Two email addresses. care@ozarihealth.com appears in the footer. support@ozarihealth.com appears in the Terms and Refund Policy.

Support timing is not reconciled. Ozari's Trustpilot company description says most patients hear back within minutes, including weekends. Its website footer lists support hours as 10am–6pm ET. Both can be true, but the site does not explain whether one is staffed support and the other is an average response claim.

A co-founder is identified only as “Lucy.” Ozari's launch release quotes “Lucy, Co-Founder of Ozari Health” without a last name. Later releases use the same first-name-only description.

None of those alone proves anything bad. Small companies have messy pages. But when you are handing over health information and a card number, mismatches are worth counting.

So is it a scam?

No. Nothing we found supports calling Ozari a scam.

But “not a scam” is a low bar. The useful question is whether its price, legal pharmacy route, medicine type, and exit terms fit what you need. A licensed clinician — not this review — decides whether a medicine is medically appropriate for you.

What does Ozari Health actually cost?

Ozari advertises compounded semaglutide from $86 a month and compounded tirzepatide from $125 a month. Neither starter price is monthly billing. They are three-month plans charged up front: $257 and $375. Ozari labels both for first-time GLP-1 users. Its live state pages list standing prices of $145 quarterly or $175 monthly for semaglutide and $199 quarterly or $235 monthly for tirzepatide. Ozari also publishes longer-plan figures elsewhere, but its public pages do not clearly say which plan the starter renews into or whether every longer plan is currently offered in every state.

This is the section most reviews get wrong, so let's go slow.

What actually hits your card today

The semaglutide headline is $257 divided by three: $85.67. It is a monthly equivalent, not a monthly charge.

Ozari does show the three-month total on the page. It is not hidden. But the large number is the monthly equivalent, and the smaller text is the amount leaving your account today. Most people notice the larger type first.

Who gets the starter price? Ozari labels it “First-Time GLP-1 Users.”

We could not find a public definition covering every edge case. Ask before paying if you used a GLP-1 years ago, briefly tried one, used an approved brand but never a compounded product, switched providers, or received a prescription but never took it.

What happens after three months

Here are the standing prices shown on Ozari's live state pages when we checked:

Now the price jump from the starter equivalent:

• Semaglutide: about $86 to $145 quarterly — about 69% more.
• Semaglutide: about $86 to $175 monthly — about 104% more.
• Tirzepatide: $125 to $199 quarterly — about 59% more.
• Tirzepatide: $125 to $235 monthly — 88% more.

Ozari's own “Save” math backs up the monthly rates. Its semaglutide page shows $257 and “Save $268.” Add them: $525 for three months, or $175 a month. Its tirzepatide page shows $375 and “Save $330.” Add them: $705 for three months, or $235 a month.

The unresolved part is renewal. We could not find a public sentence saying, “Your starter plan automatically renews into this exact plan at this exact charge.” Do not assume it becomes quarterly just because quarterly is marked popular.

The longer-plan numbers Ozari publishes elsewhere

Ozari's public pricing is not all in one place.

Its current blog says ongoing semaglutide plans start at $99 a month, and its current “true cost” pages describe Ozari semaglutide as $1,188–$2,100 per year. Its company-published May 2026 pricing dataset lists:

Those are Ozari-published numbers, not numbers we invented. But the main live treatment and state pages we loaded showed starter, quarterly, and monthly plans more clearly than the longer plans. That creates a new question: Is the $99 or six-month plan currently available to you, in your state, at checkout — and what exactly is charged up front?

Do not use a monthly equivalent as your answer. Ask for the full card charge.

Your real first-year cost

We built the first table from the live starter, quarterly, and monthly prices. These are examples, because Ozari does not publicly state which plan the starter automatically becomes.

Compounded semaglutide — first year after the starter

Compounded tirzepatide — first year after the starter

Show the math:

• $257 + ($435 × 3) = $1,562
• $257 + ($175 × 9) = $1,832
• $375 + ($597 × 3) = $2,166
• $375 + ($235 × 9) = $2,490

Ozari's separate lower long-plan figures could lower the total if those plans are available to you and the checkout terms match the published figures. That is why a single “real first-year cost” range without a billing-term label would be misleading.

Use the first-year cost calculator

Use the crawlable Ozari cost calculator below. It has three inputs:

1. Medication: semaglutide or tirzepatide
2. First-time GLP-1 user: yes, no, or not sure
3. Plan after the starter: quarterly, monthly, six-month, annual, or “I do not know”

The result should show:

• What is charged today
• The next known charge
• The 12-month total
• The monthly average
• A warning when the renewal path is not confirmed

No email wall. Keep the full fallback tables above in HTML so the answer still works without JavaScript.

One more thing we noticed

Ozari's May 19 and June 22, 2026 press releases said tirzepatide started at $120 a month.

Its live site and August 24 release say $125. Its live page carried a “Pricing last verified: July 28, 2026” note when we checked.

So the starter price moved. Five dollars is not much. The useful lesson is that press releases go stale and provider pages can disagree with each other. Use the checkout total for the current charge, then compare it with the Terms and Refund Policy. Screenshot all three.

What we still do not know about the price

We are not going to guess. These points remain unclear:

• Which plan does the starter renew into? Quarterly, monthly, or something else?
• Do you choose the renewal plan, or is one selected for you?
• Are the $99 annual and six-month prices currently available in every state?
• What full amount is charged up front for every longer plan?
• Does the base price stay flat at every dose? Ozari says flat-rate, but we did not test a higher-dose renewal.
• Could a clinician-directed change in formulation, pharmacy, or treatment change the price?
• Do replacement shipments, rush shipping, or supplies ever cost extra?

🟢 Decision point #1 — the money

You now know the real question is not “Is it $86?” It is: What leaves my account today, what leaves it next, and what does one year cost under the exact plan I am choosing?

Ozari is reasonable to keep on your list if the $257 or $375 up-front charge works, the longer-term total works, and Ozari gives you the renewal plan in writing.

Do not assume Ozari is the cheapest just because $86 is the biggest number on the page. Embody's current public terms list compounded semaglutide at $79 month-to-month and lower monthly equivalents on longer commitments. Ozari's starter is a three-month bundle. Different billing terms make the headline comparison useless unless you line up the same term.

Embody also has about 6,000 Trustpilot reviews at 3.8. Ozari has 15. Embody's downside is the same one you should watch everywhere: the lowest monthly equivalent comes with a longer commitment, and its Terms still display older inactive programs alongside current plans.

Compare current cash-pay GLP-1 plans and see the full-year cost

We may earn a commission if you choose a provider through the comparison, at no extra cost to you. The results should show the billing term, amount charged today, ongoing rate, medication type, and cancellation rule before any provider button.

Are Ozari Health's medications FDA-approved?

No. Ozari's low-cost semaglutide and tirzepatide programs use compounded prescriptions. The finished compounded products are not FDA-approved, are not generic versions of Wegovy, Ozempic, Zepbound, or Mounjaro, and are not reviewed by FDA for safety, effectiveness, or quality before sale. Ozari says its partner pharmacies operate under section 503A and fill patient-specific prescriptions. After the national semaglutide and tirzepatide shortages ended, federal rules again restricted regular copying of commercially available approved drugs. A prescriber may need to identify and document a change that makes the compounded product significantly different for the individual patient. A public sales page cannot prove that every prescription meets those conditions.

What “compounded” means in plain words

An FDA-approved medicine goes through FDA review of the drug, clinical evidence, manufacturing, and label before it can be sold for the approved use.

A compounded medicine is made or changed by a pharmacy for a specific prescription. The finished compounded product does not go through that same FDA approval process.

That does not make every compounded prescription unlawful or automatically unsafe. It means the legal path and the evidence path are different.

The cash price can be lower. But insurance coverage for an approved brand can erase or reverse that price advantage. Check coverage before deciding the compounded route is automatically cheaper for you.

The post-shortage question most pages skip

FDA says semaglutide's national injection shortage was resolved in February 2025 and tirzepatide's in December 2024. The related enforcement-discretion windows ended in 2025.

For a 503A pharmacy, FDA says the drug must be compounded for an identified patient based on a prescription. It also restricts regular or inordinate compounding of products that are essentially copies of commercially available approved drugs. One exception can apply when a prescriber determines and documents that a change creates a significant difference for that individual patient.

Ozari's footer says its compounded semaglutide and tirzepatide are prescribed for “documented individual patient need.” That is the right issue to address. We could not verify the patient-specific documentation because we did not enroll and would not have access to another patient's prescription anyway.

Ask the prescribing clinician this exact question:

“What patient-specific reason makes the compounded version appropriate for me, and will that reason be documented on my prescription?”

A clear answer is more useful than a badge or a broad statement that compounding is legal.

One thing to be careful about

There is no such thing as an “FDA-approved pharmacy.” States license pharmacies. FDA does not approve a pharmacy the way it approves a drug.

Do not accept these claims:

• “FDA-approved compounded semaglutide”
• “Generic Ozempic” or “generic Wegovy”
• “The same as the brand”
• “The same active ingredient, so it works the same”
• “Clinically proven” when the cited trial tested an approved brand, not the compounded product being sold

FDA sent warning letters to telehealth companies in March 2026 over false or misleading compounded GLP-1 promotion. To Ozari's credit, we did not find it calling the compounded finished product FDA-approved or generic.

A five-point safety check before the first dose

This does not replace your clinician or pharmacist. It is the minimum information to have in front of you:

1. The legal name of the dispensing pharmacy and its license for your state
2. The exact medicine and form on the label, including whether semaglutide is the base form rather than a salt form FDA has raised concerns about
3. Your dose in milligrams and the matching syringe units, written out by the prescriber or pharmacist
4. Storage and shipping instructions, including what to do if the package arrives warm, damaged, leaking, or late
5. A phone number for the dispensing pharmacist before you inject anything that does not match the written directions

FDA has reported dosing errors with compounded semaglutide vials, including patients drawing up the wrong amount. “Units” are not a substitute for knowing the milligram dose and concentration.

The one place Ozari's own page gets close to the line

Ozari's homepage shows “15% — Avg. weight loss.” A calculator farther down shows “Average 15% body weight loss” for semaglutide and “Average 22% body weight loss” for tirzepatide.

Those figures resemble results from trials of approved brand-name products:

• STEP 1 reported about 14.9% mean body-weight reduction at 68 weeks with approved semaglutide treatment plus lifestyle intervention.
• SURMOUNT-1 reported about 20.9% at 72 weeks at the highest tirzepatide dose studied, not 22% exactly.

Those were not Ozari trials. They did not test Ozari's compounded products.

Credit where it is due: Ozari places an “Illustrative only; not a prediction of your result” disclaimer under the calculator and says compounded medications are not FDA-approved.

The problem: the large “15%” statement near the top does not carry the same explanation next to it. A reader can easily remember the number and miss where it came from.

Treat the figures as brand-trial context, not a promise, not a typical Ozari result, and not proof about a compounded product.

Who should choose an FDA-approved path instead

You should probably start with the FDA-approved route if:

• You want the approved brand, full stop
• You have insurance and have not checked Wegovy or Zepbound coverage
• Your clinician says an approved product better fits your medical needs
• You do not have a clear patient-specific reason for a compounded version
• The lack of FDA review of the finished product will bother you every week

That last one is real. If you will feel uneasy every time you open the box, the cash savings may not be worth it.

🟢 Decision point #2 — brand vs. compounded

If this section made you want an approved brand, listen to that instinct.

Ro offers access to FDA-approved GLP-1 options, including Zepbound® (tirzepatide) and Foundayo™ (orforglipron). Ro's membership is separate from medication: $39 for the first month, then $149 month-to-month or a $74/month equivalent on a 12-month plan prepaid annually. Ro says its eligible cash-pay medication pricing matches manufacturer-direct programs such as LillyDirect, NovoCare, and TrumpRx.

Ro also offers a free GLP-1 insurance coverage checker. Have your insurance card ready. Its care team can help with prior-authorization paperwork if you enroll.

Run the coverage check before deciding that cash-pay compounding is your only affordable path.

Check whether your insurance already covers a GLP-1 — Ro's coverage checker is free

Have your insurance card ready. Medication cost is separate from Ro's membership. We may earn a commission if you enroll, at no extra cost to you.

Which pharmacy actually mails your medicine?

Ozari names Hallandale Pharmacy and VialsRx as 503A partners. Its current pharmacy page says Ozari routes the prescription based on state, treatment, dose, and capacity, so you should not assume you choose. Hallandale's FDA record is more complete than the draft first showed: a 2020 warning letter was closed out in 2022, a June 2025 Form 483 was followed by an FDA inspection-closeout letter in November 2025, and FDA's public page shows no later Hallandale warning letter. The Texas record is more complicated. License 35264 is active under BELIEVERX as a sterile-compounding pharmacy in Tomball and says “Ship Prescription Out of State: No.” A separate nearby VIALS license, 34546, says out-of-state shipping is allowed but is not marked for sterile compounding. Those are different licenses and should not be blended together.

This is the section that took the longest, and it is the one we would most want you to read.

Why the pharmacy matters more than the website

Ozari runs the platform. A pharmacy makes and labels the medicine.

If something is wrong with the vial, concentration, package temperature, or label, the dispensing pharmacy is the first place that can answer product-specific questions. Knowing its legal name and license is not a nerdy detail. It is the route the medicine took to reach you.

Hallandale Pharmacy

Hallandale operates as Pharmcore Inc., doing business as Hallandale Pharmacy, in Florida.

Its FDA history, in order:

1. March 11, 2020 — warning letter.
2. May 3, 2022 — warning-letter closeout. FDA said the violations described in the warning letter appeared to have been adequately addressed.
3. June 13, 2025 — Form 483. FDA inspectors listed observations after an inspection.
4. November 20, 2025 — FMD-145 inspection-closeout letter. FDA's public compounding-actions page records the inspection closeout.

A Form 483 is not a final agency decision that the company violated the law. The form says the observations are inspection findings and do not represent a final FDA determination.

An FMD-145 letter closes the inspection process and releases the establishment inspection report. It is not an FDA endorsement, accreditation, or promise that no future issue can occur.

That gives you the proportionate version — not “Hallandale has an unresolved 2020 warning,” and not “Hallandale has a spotless record.” The old warning was closed. A later inspection produced observations, and that inspection was later closed through FDA's inspection process.

VialsRx, BELIEVERX, and the two Texas licenses

Ozari calls its second partner VialsRx. The Texas records show two nearby but separate pharmacy licenses:

The March 18, 2026 inspection paperwork for license 35264 records a move from a Houston address to Tomball and a name change from VIALSRX to BELIEVE RX. The warning-notice attestation shows zero listed deficiencies for that inspection.

A trade name can differ from a legal license name. A company can also have more than one entity or permit. That is normal.

But the two records do not answer the patient question by themselves:

Which exact legal pharmacy license compounds and ships the injectable prescription into my state?

The sterile-compounding license says no out-of-state prescription shipping. The separate license that says yes to out-of-state shipping is not marked as the sterile-compounding license. We are not saying anyone is shipping illegally. There may be other state permits, entities, fulfillment arrangements, or updated records. Ozari's public page does not connect those dots.

That is the mismatch. Do not solve it by assuming the two licenses are interchangeable.

Do you get to choose your pharmacy?

Two Ozari sources say different things.

The current page is the better guide to current process. If pharmacy choice matters to you, ask before paying and get the answer in writing.

How to check any pharmacy in five minutes

This works for Ozari and every other online provider.

1. Ask: “What is the exact legal name and license number of the pharmacy that will fill my prescription in my state?”
2. Search that license on the pharmacy board site for the pharmacy's home state.
3. Check your own state board for a nonresident permit when one is required.
4. Confirm the address matches what the company told you.
5. If the prescription is injectable, confirm the license covers sterile compounding.
6. Ask whether a different license or entity handles out-of-state fulfillment.
7. When the box arrives, read the label. It should name the dispensing pharmacy.
8. If the name, concentration, or instructions do not match what you were told, call the dispensing pharmacist before injecting.

Five minutes will not audit the whole supply chain. It will catch the easiest and most important mismatch: paying one company while not knowing which legal pharmacy made the product.

What do Ozari Health reviews really say?

Ozari had 15 public Trustpilot reviews and a 4.2 rating when we checked: 60% five-star, 33% four-star, and one two-star review. Fourteen of the 15 visible review posting dates fell inside one eight-day window, June 20–27, 2026. Trustpilot says Ozari asks customers for reviews and has not replied to negative reviews. The feedback leans positive on speed and support, but 15 posts cannot prove long-term billing, shipping, medication quality, or cancellation reliability.

The whole review record fits on one screen

You came here to read Ozari Health reviews. There are 15 on Trustpilot. You can read every one in a few minutes.

So we did.

For context on the same platform when checked, Embody had about 6,000 reviews at 3.8, and bmiMD had 868 at 4.4.

Three things we noticed reading them

One: almost all arrived in one burst. Fourteen of the 15 posting dates fell between June 20 and June 27. Trustpilot says Ozari invites customers to review and says those invitations can go to customers with positive or negative experiences. Asking is allowed. The tight date cluster still means the rating is an early campaign-shaped sample, not years of organic history.

Two: two reviews use the same wording. A reviewer listed as “Mark Clark” posted a four-star review on June 23. A reviewer listed as “Arjun Mehta” posted on June 22. The review text is identical even though the star ratings differ.

We are not going to tell you why. We are showing you what is visible so you can look and decide.

Three: the only negative review is the one Ozari did not answer. The positive reviews received warm replies. The two-star review did not. Trustpilot's transparency label says the company has not replied to negative reviews.

What people actually said

Here are short excerpts from public posts:

“No upsells, no pressure, just straightforward care.” — Emma, 5★, June 21, 2026

“Very quick response and follow up. Excellent service.” — stevewolgin, 5★, June 21, 2026

And the two posts that show the other side:

Elaine Midgett, 4★, updated June 22, 2026, wrote that she wanted to cancel before shipment and get a refund. Ozari replied publicly that it canceled the order before shipment and processed the refund.

That is evidence of what Ozari says it did in one case. The customer did not post a later update confirming that the money reached her account, so this page will not upgrade it into a confirmed completed refund.

Tomi Sue Wille, 2★, July 10, 2026, wrote that she asked for a microdosing program and was approved for a regular tirzepatide dose. Ozari did not post a reply.

One post is not a pattern. It is still a reason to confirm the exact prescribed plan before the prescription goes to the pharmacy.

These are individual public posts. We did not verify the reviewers' identities or medical records. Trustpilot says Ozari invites customers to review. The excerpts describe service, not medicine safety and not typical weight-loss results.

What about Reddit?

There is very little independent Reddit discussion about Ozari compared with older GLP-1 platforms.

That is not proof of a problem. It means you cannot crowd-check billing, shipping, support, and cancellation across hundreds of unprompted threads yet. Treat any brand-owned or brand-moderated community as company media unless its independence is clear.

Bottom line on the reviews

Can you actually cancel Ozari Health?

Ozari's public documents do not give one clean answer. The homepage says “Cancel anytime.” The Terms of Service, dated February 15, 2026, say subscription products require a minimum three-month commitment and cancellation 15 days before the next processing date, after the commitment ends, by email. A June release says there are no long-term contracts. The Refund Policy, updated August 2026, says text is faster than email and says early cancellation of annual or semiannual plans re-prices used months at the standard monthly rate. Get the controlling rule for your exact plan in writing before paying.

This is our single biggest finding, so we are showing it straight.

Four documents. One question. Four answers.

Four Ozari sources. Four versions of what flexibility means.

It gets stranger

The Terms tell you to cancel by email.

The Refund Policy says text is the fastest way and warns email may not be reviewed in time to stop pharmacy transmission.

Those instructions are not identical. They may cover two different moments — stopping the next subscription charge versus stopping the current order before the pharmacy gets it — but the public wording does not make that split clear.

The Terms also state: “The purchase of Products are non-refundable.”

The Refund Policy is more detailed and newer, but the page does not say it overrides the Terms.

Could both be true?

Maybe. These explanations could reconcile parts of it:

• The minimum applies only to some subscription products
• The starter plan itself is the three-month commitment
• “Canceling future renewal” and “stopping the current order before pharmacy transmission” are different actions
• The newer Refund Policy controls operational steps while the older Terms were not updated
• Long-plan re-pricing applies only to annual and semiannual plans

The problem is not that one of those must be sinister. The problem is that you cannot tell which one controls your checkout from the public wording.

The part that can cost the most money

For annual and semiannual plans, Ozari says it re-prices the months already used at its standard monthly rate, then refunds the remaining balance.

That means “halfway through” does not necessarily mean “half your prepayment comes back.”

Illustrative semaglutide example using Ozari's own published figures:

• Annual plan implied total: $1,188
• Six months used
• Used months re-priced at $175 × 6 = $1,050
• Possible remaining amount before any other permitted adjustment: $138, not $594

Illustrative tirzepatide six-month example:

• Six-month plan in Ozari's May dataset: $1,050
• Three months used
• Used months re-priced at $235 × 3 = $705
• Possible remaining amount before any other permitted adjustment: $345, not $525

Those are math examples, not promises of a refund. The exact plan, timing, prescription status, and policy wording control.

What Ozari gets right here

Parts of the Refund Policy are more direct than many provider pages.

Ozari says the window between checkout and pharmacy transmission can be short and is never guaranteed. It says a compounded prescription cannot be returned once prepared for an individual patient. It also explains the long-plan re-pricing rule instead of hiding it until cancellation.

A public Trustpilot exchange shows Ozari saying it canceled one order before shipment and processed a refund. The customer did not post a later receipt confirmation, so we are treating that as one company-stated example, not proof of a completed refund system.

That is still more useful than silence. It just does not line up cleanly with “Cancel anytime.”

If you sign up anyway, do these four things

We earn nothing from Ozari. Take this as straight advice.

1. Screenshot the final checkout page with the plan name, term, amount charged today, renewal amount, and renewal date.
2. Choose the shortest term that actually fits your needs after comparing the up-front charge and early-exit rule.
3. Set a reminder 21 days before renewal. The Terms say 15 days; use the extra six as a buffer.
4. Send any cancellation by email and text. Ask for written confirmation that covers both the current pharmacy order and future renewal.

Do not delete the confirmation after the charge stops. Save it with the original checkout screenshot.

Why this matters beyond Ozari

The FTC's 2024 negative-option rule was vacated by a federal appeals court on July 8, 2025 because of the rulemaking process, so that version did not take effect. The FTC opened a new rulemaking process in March 2026.

The underlying Restore Online Shoppers' Confidence Act still applies to covered online negative-option sales. It requires clear disclosure of material terms before billing, informed consent, and a simple way to stop recurring charges. The FTC also says companies should not block the cancellation method they promised and should honor proper cancellation requests.

We are not accusing Ozari of violating the law. We are saying the promise, Terms, release, and Refund Policy should say the same thing before a customer enters a card number.

🟢 Decision point #3 — flexibility

If being able to stop quickly is your priority, this is where Ozari struggles.

Here is the honest Embody comparison, including the part that needs watching.

Embody's current public terms list active semaglutide pricing of $79 month-to-month, $76 on a three-month plan, $73 on six months, and a $69 monthly equivalent on an annual plan. The lower number requires a longer commitment. Its Terms also retain older programs that are clearly marked “NO LONGER ACTIVE,” including a $99 first month followed by $299 refills.

So the problem is not that the same active plan randomly costs $69, $79, or $99 depending on a link. The real issue is that the number changes with the commitment, while old inactive terms remain on the page. Confirm the active plan name, up-front charge, and cancellation deadline.

Embody has about 6,000 Trustpilot reviews you can sort tonight. Ozari has 15. More reviews do not make Embody automatically better, but they give you more complaints, replies, and long-term patterns to inspect.

Show me programs with clearer exit terms

The comparison should put commitment length and cancellation rules before price. See our GLP-1 cancellation guide before choosing a longer term. We may earn a commission if you choose a provider through it, at no extra cost to you.

Do Ozari's testimonial timelines add up?

Ozari's homepage displayed 28 named testimonial entries under “Real results” when we checked. Several describe 14 months, 22 months, or about two years of treatment, including losses over 100 pounds. Ozari announced its nationwide platform launch on May 19, 2026 — just over three months before this review. A nationwide-launch date is not necessarily the date the first patient received care, so the timelines can have ordinary explanations. But Ozari does not publish that explanation next to the testimonials, and the testimonial area does not carry the calculator's “illustrative” label.

We debated whether to include this. We are including it because we would want to know.

The two facts, side by side

What the testimonial entries say:

• “Two years in and I'm down 110 pounds.”
• “Two years later I'm down 110 pounds, off metformin.”
• “107 pounds down in just under 2 years.”
• “106 pounds down over 22 months. I'm never leaving.”
• Duration listed as “22–24 months.”
• “That was 14 months ago.”

What Ozari's public timeline says:

What we are saying — and what we are not

We are not saying the people do not exist. We are not saying the testimonials were fabricated. We are not treating the launch release as proof that nobody received related care before May.

A company can operate quietly before a nationwide announcement. It can run a pilot. It can use a predecessor business. Its clinicians may have treated patients through another network. A marketing launch date is not a medical-record start date.

But Ozari does not explain which of those applies.

Ozari clearly knows how to label a projection. Its calculator says the figures are illustrative and not a prediction. The testimonial carousel says “Real results” without a nearby statement explaining whether these are Ozari patients, clinician-network patients, predecessor-program patients, paid testimonials, or examples licensed from another source.

So do not treat those entries as proof that this specific platform has two years of results until Ozari explains the source and timeline.

The clean question is:

“When did each person's treatment begin, through which program, and did Ozari verify the result from records?”

How to run this check on any provider

1. Search the brand name plus “launches” or “announces.”
2. Find the oldest dated company page or press release.
3. Compare that public timeline with the longest testimonial.
4. Look for a statement explaining predecessor programs, clinician networks, incentives, and result verification.

A testimonial older than the public brand timeline is not proof of fraud. It is a fact that needs an explanation before you use it as evidence.

What three questions does Ozari still need to answer?

We found no public answer to these three questions as of August 25, 2026.

1. Which cancellation rule controls each current plan — the three-month minimum in the Terms, the “cancel anytime” homepage promise, or the cancel-before-pharmacy language in the Refund Policy?

2. Do patients choose Hallandale Pharmacy or VialsRx, or does Ozari assign the pharmacy? The May launch release and current pharmacy page say different things.

3. Which exact legal pharmacy entity and license compound and ship injectable prescriptions outside Texas when license 35264 is marked “Ship Prescription Out of State: No,” while the separate out-of-state VIALS license is not marked for sterile compounding?

Publication rule: Do not change this section to “we asked Ozari” unless the questions were actually sent and the sent message is saved. Once sent, add the date, addresses used, and response status. Publish any substantive answer in full or link to the full answer, then date every resulting correction.

If Ozari answers clearly, our verdict can move up. If you are an Ozari customer, clinician, pharmacy, or employee with documentation that resolves a point, use the corrections address listed on this site.

Which Ozari Health claims are verified?

This table separates what Ozari says from what an outside record confirms. “Provider-stated” means Ozari publishes it. “Verified” means a government record or independent platform supports the narrow claim. “Conflict” means two current or still-public records disagree. “Not verified” means we did not find enough public proof.

Bookmark this. It is the whole review in one place.

Money and service

Company, medicine, pharmacy, and track record

What would change our verdict

We are not trying to make the standard impossible. These facts would move Ozari up:

• One cancellation rule that clearly controls every live plan
• A public renewal rule for the starter plan
• A state-by-state pharmacy table with the legal entity and license number
• A clear explanation of licenses 35264 and 34546 and the sterile out-of-state route
• An explanation of the testimonial source and timeline
• Long-plan prices shown with the full amount charged up front
• A much larger independent review record without a damaging pattern
• A documented firsthand test of intake, prescribing, shipping, support, billing, and cancellation

Who does Ozari Health fit — and who should skip it?

Ozari fits a narrow person: a first-time GLP-1 user paying cash who is comfortable with a compounded prescription, can pay $257 or $375 up front, and will confirm the renewal price, patient-specific compounding reason, dispensing pharmacy, and cancellation rule before paying. It is a weak fit for anyone who needs an FDA-approved brand, insurance help, a chosen pharmacy, quick cancellation, or a long public track record.

Find yourself in this table.

The three things that must be true before you pay

Not just for Ozari. For anyone.

1. The money is clear. You know what hits your card today, the plan term, the next charge, and the first-year total.

2. The medicine route is clear. You know whether it is approved or compounded. For compounded medicine, you know the patient-specific reason, legal pharmacy name, license, concentration, and state authorization.

3. The exit is clear. You know the cancellation deadline, the pharmacy-transmission cutoff, refund rule, re-pricing rule, and minimum commitment. In writing.

If all three are clear, you are not guessing. You are making a decision.

How does Ozari compare with other paths?

Ozari's advantage is a low three-month starter rate for eligible first-time cash-pay users. Its disadvantages are the up-front bundle, compounded rather than FDA-approved medication, a tiny public review record, unclear starter renewal, and conflicts in its own cancellation and pharmacy documents. The right path depends on which problem you are trying to solve — not which page has the smallest number in the largest font.

We are deliberately not turning an Ozari review into a 20-provider ranking. The full provider comparison should live on a separate page, with the same billing-term and medicine-type labels used here.

Internal link: Compare GLP-1 providers by FDA status, amount charged today, first-year cost, pharmacy disclosure, and exit terms.

What should you check before paying any online GLP-1 provider?

These nine checks take about ten minutes and work on almost any online GLP-1 company. If you only do three, check the amount charged today, the cancellation section in the Terms, and the legal pharmacy name.

Take this with you. Use it on us too.

That press-release check is worth explaining because it can make a new company look older than it is.

Search Ozari and you may see the same announcement on GlobeNewswire, Yahoo Finance, AP syndication pages, Benzinga, BioSpace, and other outlets. That does not mean five reporters investigated the company. A wire release is company-supplied material distributed across a network.

Look for “GLOBE NEWSWIRE,” “Source: [Company],” or identical wording. Treat it as evidence of what the company said on that date — not outside verification.

The same rule applies to our page. A provider statement stays labeled provider-stated until an outside record confirms it.

How did we review Ozari Health?

We built this review from Ozari's own live pages and legal documents, government pharmacy and FDA records, independent review-platform data, and the published rules that control compounded drugs and recurring online charges. We separated provider statements from outside confirmation. We did not enroll, receive medicine, or test the service.

What we used, in order of weight

1. FDA records and guidance — shortage status, compounding rules, warning letters, closeouts, Form 483s, and inspection-closeout entries
2. State pharmacy-board records — legal names, addresses, license classes, sterile scope, shipping fields, and inspection documents
3. Ozari legal and pricing pages — Terms, Refund Policy, treatment, state, pharmacy, FAQ, blog, and company dataset
4. Independent review platforms — Trustpilot profile, dates, star distribution, and company replies
5. Company press releases — used as dated statements by Ozari, never as independent reporting
6. Clinical trial publications — used only to identify where brand-trial percentages came from
7. Community discussion — used to understand questions people ask, not as proof of medical or regulatory facts

How we handled conflicts

When two records disagree, we do not quietly choose the nicer one. We show both, date both, and explain what remains unresolved.

That is why this page says “we do not know” more often than most provider reviews. A dated uncertainty is more useful than a confident guess.

Our money policy

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission if you use some links. That does not change the facts we publish, and no provider gets to edit the verdict.

Ozari pays us nothing. We do not earn more if you choose Ozari, and we do not earn less if you skip it.

Affiliate CTAs on this page come only after the reader reaches the decision that makes the alternative relevant: money, approved versus compounded, flexibility, or final matching. Provider links must never replace the answer.

Corrections

Found something wrong? Send the primary record and the exact sentence. We publish material corrections with dates. If Ozari answers the three unresolved questions, we will publish or link the complete substantive answer and show whether the verdict changed.

Revision log

Ozari Health FAQ

Is Ozari Health legit?
Ozari appears to be an operating telehealth platform. Its Terms identify Ozari LLC, its pages name clinicians and pharmacy partners, and nothing we found supports calling it a scam. It is still very new, has only 15 public Trustpilot reviews, and has unresolved document conflicts.

Is Ozari Health a scam?
No. Nothing we found supports that label. The useful questions are what you are charged, which legal pharmacy fills the prescription, why a compounded product is patient-specific, and how you get out.

How much does Ozari Health charge up front?
The starter plans show $257 for three months of compounded semaglutide or $375 for three months of compounded tirzepatide, for eligible first-time GLP-1 users. Confirm the final checkout amount.

Why does Ozari say semaglutide is $86 a month?
Because $257 divided by three is $85.67. It is a monthly equivalent for a three-month prepayment, not monthly billing.

Who qualifies for Ozari's starter price?
Ozari labels it for first-time GLP-1 users. Its public pages do not define every prior-use edge case. Ask before entering payment if you have ever been prescribed or taken a GLP-1.

What happens after the starter plan ends?
Ozari's live pages show $145 quarterly or $175 monthly for semaglutide and $199 quarterly or $235 monthly for tirzepatide. We could not confirm which plan the starter automatically becomes.

Does Ozari have annual or six-month plans?
Ozari's Refund Policy refers to annual and semiannual plans. Its current blog and true-cost pages say semaglutide can run from $99 a month or $1,188 a year, and its May 2026 company dataset lists six-month rates of $120 a month for semaglutide and $175 for tirzepatide. Confirm current checkout availability, full up-front charge, and state access before relying on those figures.

What is Ozari's first-year cost?
Using the live starter plus quarterly prices, semaglutide is $1,562 and tirzepatide is $2,166. Using the starter plus month-to-month prices, they are $1,832 and $2,490. Longer plans could change the total if currently offered to you.

Does Ozari charge more at higher doses?
Ozari describes its plans as flat-rate. We did not complete a higher-dose renewal, so get that promise in writing for the exact plan and formulation.

Are Ozari's medications FDA-approved?
No. The low-cost semaglutide and tirzepatide programs are compounded. The finished products are not FDA-approved and are not generic versions of approved brands.

Why can compounded semaglutide or tirzepatide still be prescribed after the shortages ended?
Section 503A can allow patient-specific compounding when its conditions are met. FDA restricts regular copying of commercially available approved drugs. A prescriber may need to document a change that creates a significant difference for the individual patient. Ask what that documented reason is for you.

Is Ozari's semaglutide generic Ozempic or Wegovy?
No. A compounded prescription is not an FDA-approved generic version of either brand.

Are the 15% and 22% weight-loss figures Ozari results?
Not based on evidence we found. They resemble results used from trials of approved brand-name products. Ozari's calculator labels the figures illustrative. Do not treat them as typical results for Ozari or a compounded product.

What pharmacy does Ozari use?
Ozari names Hallandale Pharmacy and VialsRx. Its current page says routing depends on state, treatment, dose, and capacity.

Can I choose the Ozari pharmacy?
Do not assume so. The launch release says patients choose, while the current pharmacy page says Ozari routes the prescription.

What is VialsRx or BELIEVERX?
Texas license 35264 is currently listed as BELIEVERX, a sterile-compounding community pharmacy in Tomball. A March 2026 inspection records a VIALSRX-to-BELIEVE RX transition. A separate nearby VIALS license, 34546, has different scope and shipping fields. Ask which exact license fills your prescription.

Can BELIEVERX ship Ozari injections outside Texas?
The public profile for sterile-compounding license 35264 says “Ship Prescription Out of State: No.” A separate VIALS license says yes but is not marked for sterile compounding. There may be other permits or entities, but Ozari's public page does not explain the route. Ask for the legal entity and your-state permit.

Does Hallandale Pharmacy have an FDA warning?
It received a warning letter in 2020. FDA closed that warning in May 2022. A June 2025 Form 483 was followed by an inspection-closeout entry in November 2025. A Form 483 is not a final violation finding, and an inspection closeout is not an FDA endorsement.

Is Ozari available in all 50 states?
Ozari uses nationwide language and publishes state pages. Actual access requires a clinician authorized in your state and a pharmacy legally able to fill and ship the prescription there. Confirm both.

Can I cancel Ozari anytime?
We cannot give a clean yes. The homepage says “cancel anytime.” The Terms say a three-month minimum and 15-day notice after the commitment. Get the controlling rule for your exact plan in writing.

Does Ozari offer refunds?
Its Refund Policy says an order may be stopped before pharmacy transmission but becomes final after that point. Its Terms also say product purchases are non-refundable. Ozari publicly said it processed one pre-shipment refund; the customer did not later confirm receipt in the public thread.

What happens if I cancel an annual or semiannual plan early?
Ozari says used months are re-priced at its higher standard monthly rate before the remaining balance is refunded. That can reduce the refund sharply.

Does Ozari take insurance?
No. It is presented as a cash-pay program. Check approved-brand insurance coverage before assuming cash pay is cheaper.

Can I use an HSA or FSA with Ozari?
Ozari says it accepts HSA and FSA cards. Your plan administrator decides whether a particular expense is eligible and what records are required.

How long does Ozari shipping take?
Ozari advertises free three-to-five-day shipping and provider review within 24 hours. Those are provider estimates, not guarantees. Ask what happens if cold-chain medicine arrives late or warm.

Does Ozari offer microdosing?
One two-star reviewer said she requested a microdosing program and was approved for a regular dose. One post does not prove a pattern. Confirm the exact prescribed dose and plan before pharmacy transmission.

Are Ozari Health reviews trustworthy?
They are public posts on an independent platform, but we did not verify each identity or medical record. The sample is only 15, 14 posting dates fell in one eight-day window, and Trustpilot says Ozari invites reviews. Use them as an early service signal, not proof of long-term reliability or medical results.

Are Ozari's long-term testimonials verified?
Ozari labels them “Real results,” but we found no nearby explanation of when treatment began, which program provided it, or how Ozari verified the result. Several timelines predate the public nationwide launch by more than a year. That needs an explanation, not an accusation.

Our final take

Ozari looks like a real platform trying to do a real thing. It names clinicians. It names pharmacy partners. It says the compounded products are not FDA-approved. Its Terms did not contain forced arbitration when we checked.

We want to be clear about that, because it would be easy to read this page as a hit piece. It is not one.

But you came here for Ozari Health reviews, and there are 15. Fourteen posting dates fell into eight days. The homepage says “cancel anytime” while the Terms say a three-month minimum. The $86 is a $257 charge. The starter renewal is not clearly stated. And the testimonial section describes up to two years of results on a public brand timeline that shows a nationwide launch just over three months before this review.

None of that makes Ozari a scam. All of it makes Ozari unproven right now — and unproven is a hard thing to hand a card and a prescription decision to without written answers.

Here is what we would tell a friend: if you are paying cash, you are new to GLP-1s, you can afford the full three-month charge, you understand the medicine is compounded, and you get the renewal, pharmacy license, patient-specific reason, and cancellation rule in writing first, Ozari is reasonable to consider.

The starter price is low. It is not automatically the lowest current cash-pay path once billing terms are aligned. The value comes from the whole deal — medicine route, pharmacy, term, support, and exit — not the first number.

If you cannot get clear answers, the month-four total does not work, you may need to stop, or you would sleep better with an FDA-approved medicine, use another path.

And one more thing, because it needs saying.

Wanting a GLP-1 is not something you need permission for. It is not a moral failure and it is not cheating. These are medicines that can help some people with a hard, long-term health problem. Being careful about where you get one is exactly the right instinct.

You are not being paranoid. You are being smart with your money and your body. Now finish the check before you finish the checkout.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Nine questions about your budget, state, insurance, medication preference, billing-term comfort, and whether you are open to compounded medicine.

The result should show a personalized shortlist with:

• FDA-approved versus compounded clearly labeled
• Amount charged today
• Ongoing price and first-year total
• Published cancellation terms and any conflicts
• Named pharmacy information where available
• The main downside before the provider button

Get my personalized GLP-1 action plan

Sources

All pages and records were checked August 25, 2026 unless another verification date is stated.

Ozari Health pages

• Homepage — https://www.ozarihealth.com/
• Terms of Service — https://www.ozarihealth.com/terms
• Refund & Cancellation Policy — https://www.ozarihealth.com/refund-policy
• Pharmacy Standards — https://www.ozarihealth.com/pharmacy-standards
• Compounded Semaglutide — https://www.ozarihealth.com/treatments/semaglutide
• Compounded Tirzepatide — https://www.ozarihealth.com/treatments/tirzepatide
• Semaglutide state pricing example — https://www.ozarihealth.com/compounded-semaglutide/new-jersey
• Tirzepatide state pricing example — https://www.ozarihealth.com/compounded-tirzepatide/connecticut
• GLP-1 FAQ — https://www.ozarihealth.com/glp1-faq
• Ozari blog pricing statement — https://www.ozarihealth.com/blog
• Ozari GLP-1 pricing dataset — https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026
• Ozari true-cost page showing the published $1,188–$2,100 semaglutide range — https://www.ozarihealth.com/true-cost/mystart-health

Ozari press releases

• Nationwide launch announcement, May 19, 2026 — GlobeNewswire/BioSpace distribution
• GLP-1 pricing-data announcement, May 26, 2026 — GlobeNewswire
• Online GLP-1 provider checklist, June 22, 2026 — GlobeNewswire
• Transparency-review release, July 9, 2026 — openPR
• Updated pricing release, August 24, 2026 — GlobeNewswire

Independent review records

• Ozari Health on Trustpilot — https://www.trustpilot.com/review/ozarihealth.com
• Embody on Trustpilot — https://www.trustpilot.com/review/joinem.com
• bmiMD on Trustpilot — https://www.trustpilot.com/review/bmimd.com

FDA and pharmacy records

• FDA: Compounding inspections, recalls, and other actions — https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
• FDA: Pharmcore Inc. dba Hallandale Pharmacy warning-letter closeout, May 2022
• FDA: Pharmcore Inc. dba Hallandale Pharmacy Form 483, June 13, 2025
• FDA: Compounding when drugs are on FDA's Drug Shortages List — https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list
• FDA: GLP-1 shortage and post-shortage compounding-policy updates — https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
• FDA: Concerns with unapproved GLP-1 drugs used for weight loss — https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• FDA: Telehealth-company promotion of compounded drugs and March 2026 warning letters
• FDA: Locate a state-licensed online pharmacy
• Texas State Board of Pharmacy, license 35264 — https://www.pharmacy.texas.gov/dbsearch/phy_zoom.asp?id=35264
• Texas State Board of Pharmacy, license 34546 — https://www.pharmacy.texas.gov/dbsearch/phy_zoom.asp?id=34546
• Texas State Board of Pharmacy inspection documents, March 18, 2026, for licenses 35264 and 34546

Clinical-trial context

• STEP 1 trial: Wilding et al., New England Journal of Medicine (2021)
• SURMOUNT-1 trial: Jastreboff et al., New England Journal of Medicine (2022)

Recurring-charge law and policy

• Restore Online Shoppers' Confidence Act, 15 U.S.C. § 8403
• FTC negative-option rule vacatur, Eighth Circuit, July 8, 2025
• FTC Advanced Notice of Proposed Rulemaking on negative-option marketing, March 2026
• FTC Health Products Compliance Guidance

Alternative-route facts used in decision boxes

• Embody homepage — https://joinem.co/
• Embody Terms & Conditions — https://joinem.co/pages/terms-conditions
• Ro Weight Loss pricing — https://ro.co/weight-loss/pricing/
• Ro GLP-1 Insurance Coverage Checker — https://ro.co/weight-loss/glp1-insurance-checker/

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. This page is for information only and is not medical advice. We are not doctors. Only a licensed provider can decide whether a GLP-1 medication is right for you. Individual results vary. Compounded medications are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality.

Last verified: August 25, 2026.